Tr1X
Phase 1/2Tr1X is developing a novel class of regulatory T cell-based therapies to cure autoimmune and inflammatory diseases and transform patient lives.
Founded
2022
Focus
Cell & Gene Therapy
About
Tr1X is developing a novel class of regulatory T cell-based therapies to cure autoimmune and inflammatory diseases and transform patient lives.
Funding History
1Total raised: $75M
Seed$75MThe Column GroupOct 15, 2023
Company Info
TypePrivate
Founded2022
LocationSan Diego, United States
StagePhase 1/2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile